13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
33 檔
29.2%
According to the latest 13F quarterly dataset, Commodore Capital LP managed an equity portfolio of $1.7B at the end of Q4 2025, spanning 33 distinct U.S. exchange-listed positions.
In Q4 2025, Commodore Capital LP adopted a defensive or profit-taking posture, trimming 12 positions and completely liquidating 10 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RLAY | Relay Therapeutics Inc | Stock-Other | 9.57% | +3.58% | — | |
| 2 | ALKS | Alkermes plc | Stock-Healthcare | 6.61% | +0.77% | +14.64% | |
| 3 | TYRA | Tyra Biosciences Inc | Stock-Other | 5.91% | -1.91% | — | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.37% | -2.78% | EXIT | |
| 5 | SYRE | Spyre Therapeutics Inc | Stock-Other | 5.21% | -1.10% | +20.13% | |
| 6 | COGT | Cogent Biosciences Inc | Stock-Other | 5.19% | +0.60% | -69.70% | |
| 7 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.81% | +2.47% | — | |
| 8 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.64% | -1.96% | -15.30% | |
| 9 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 4.54% | +1.50% | +38.63% | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.97% | — | -74.12% | |
| 11 | KYMR | Kymera Therapeutics Inc | Stock-Other | 3.88% | -1.90% | — | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.70% | -1.26% | EXIT | |
| 13 | NUVL | Nuvalent Inc-a | Stock-Other | 3.68% | -4.20% | -60.71% | |
| 14 | ORKA | Oruka Therapeutics Inc | Stock-Other | 3.54% | — | — | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 3.49% | -0.21% | -21.87% | |
| 16 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.87% | -2.04% | EXIT | |
| 17 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.62% | — | -56.10% | |
| 18 | ASMB | Assembly Biosciences Inc | Stock-Other | 2.26% | +0.71% | — | |
| 19 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 2.22% | +0.76% | — | |
| 20 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 2.18% | — | — | |
| 21 | ANRO | Alto Neuroscience Inc | Stock-Other | 2.16% | +0.74% | — | |
| 22 | PALI | Palisade Bio Inc | Stock-Other | 1.79% | -0.73% | EXIT | |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.78% | — | -37.98% | |
| 24 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.66% | — | -64.91% | |
| 25 | PEPG | Pepgen Inc | Stock-Other | 1.47% | +0.02% | +44.23% | |
| 26 | SABS | Sab Biotherapeutics Inc | Stock-Other | 1.10% | -0.31% | — | |
| 27 | REPL | Replimune Group Inc | Stock-Other | 0.92% | — | — | |
| 28 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.74% | +0.13% | — | |
| 29 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.62% | — | — | |
| 30 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.58% | +0.70% | — | |
| 31 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.56% | — | — | |
| 32 | LONA | Leonabio Inc | Stock-Other | 0.23% | -0.03% | — | |
| 33 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.10% | — | -96.23% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RLAY | Relay Therapeutics Inc | +5.2% | — | Unchanged |
| 2 | TYRA | Tyra Biosciences Inc | +3.6% | — | Unchanged |
| 3 | SYRE | Spyre Therapeutics Inc | +3.6% | +20.13% | Add |
| 4 | ALKS | Alkermes plc | +2.1% | +14.64% | Add |
| 5 | ORKA | Oruka Therapeutics Inc | +1.9% | — | Unchanged |
| 6 | 430 | Terns Pharmaceuticals Inc | +1.9% | -74.12% | Trim |
| 7 | AMLX | Amylyx Pharmaceuticals Inc | +1.8% | +38.63% | Add |
| 8 | KYMR | Kymera Therapeutics Inc | +1.8% | — | Unchanged |
| 9 | NRIX | Nurix Therapeutics Inc | +1.2% | -39.82% | Trim |
| 10 | LBRX | Lb Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 11 | ASMB | Assembly Biosciences Inc | +1% | — | Unchanged |
| 12 | CTMX | Cytomx Therapeutics Inc | +1% | — | Unchanged |
| 13 | PEPG | Pepgen Inc | +0.9% | +44.23% | Add |
| 14 | CLDX | Celldex Therapeutics Inc | +0.8% | -15.30% | Trim |
| 15 | SABS | Sab Biotherapeutics Inc | +0.7% | — | Unchanged |
| 16 | PHVS | Pharvaris N.V. | +0.5% | -21.87% | Trim |
| 17 | IKT | Inhibikase Therapeutics Inc | +0.3% | — | Unchanged |
| 18 | AVTX | Avalo Therapeutics Inc | +0.3% | — | Unchanged |
| 19 | ELVN | Enliven Therapeutics Inc | +0.1% | — | Unchanged |
| 20 | COGT | Cogent Biosciences Inc | +0.1% | -69.70% | Trim |
| 21 | XENE | Xenon Pharmaceuticals Inc | +0.1% | -33.33% | Trim |
| 22 | BRD1EUR | Mind Medicine Mindmed Inc | -0.1% | -37.98% | Trim |
| 23 | PTGX | Protagonist Therapeutics Inc | -0.7% | -56.10% | Trim |
| 24 | SLNOEUR | Soleno Therapeutics Inc | -0.8% | -11.11% | Trim |
| 25 | DRUG | Bright Minds Biosciences Inc | -1.4% | -96.23% | Trim |
| 26 | 260 | Centessa Pharmaceuticals-adr | -1.7% | -64.91% | Trim |
| 27 | NUVL | Nuvalent Inc-a | -2.2% | -60.71% | Trim |
| 28 | ✓ | Merus N V | — | EXIT | Sold out |
| 29 | AGIO | Agios Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | VRDN | Viridian Therapeutics Inc | — | EXIT | Sold out |
| 31 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 32 | ANRO | Alto Neuroscience Inc | — | NEW | New buy |
| 33 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 34 | REPL | Replimune Group Inc | — | NEW | New buy |
| 35 | TNGX | Tango Therapeutics Inc | — | EXIT | Sold out |
| 36 | APGE | Apogee Therapeutics Inc | — | EXIT | Sold out |
| 37 | ENTA | Enanta Pharmaceuticals Inc | — | EXIT | Sold out |
| 38 | CTNM | Contineum Therapeutics Inc-a | — | NEW | New buy |
| 39 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 40 | ✓ | — | EXIT | Sold out | |
| 41 | VTGN | Vistagen Therapeutics Inc | — | EXIT | Sold out |
| 42 | ✓ | Crescent Biopharma Inc. | — | EXIT | Sold out |
| 43 | LONA | Leonabio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 33 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RLAY, ALKS, TYRA) accounted for 29.2% of total reported equity market value during Q4 2025.
Top New Position Initiated
ANRO
市值: $32.5M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $331.9M
During Q4 2025, Commodore Capital LP's top holdings by market value included RLAY (9.6%)、ALKS (6.6%)、TYRA (5.9%). The largest single position, RLAY, represented 9.6% of total portfolio value.
In Q4 2025, Commodore Capital LP made 32 total portfolio adjustments, initiating 6 new buys, adding to 4 positions, trimming 12 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.